Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Vulval and vaginal cancer red flags

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Major bleeding or obstructive complications

Heavy genital bleeding, haemodynamic compromise, urinary retention, bowel obstruction, sepsis, severe uncontrolled pain or new thromboembolic symptoms can accompany advanced vulval or vaginal malignancy.

Action: Assess airway, breathing and circulation, obtain intravenous access and urgent blood tests, control haemorrhage where possible, treat sepsis or obstruction, and involve acute gynaecology and gynaecological oncology immediately.

Synopsis

Recognise suspicious vulval and vaginal findings promptly, separate symptomatic diagnosis from cervical screening, and initiate consented examination, urgent referral, biopsy and specialist staging safely.

  • Inspect the entire vulva, perineum and perianal skin in good light; a symptom described as vaginal may arise from the vulva, urethra, vagina or cervix.
  • NICE advises considering a suspected-cancer pathway referral for an unexplained vulval lump, ulceration or bleeding and for an unexplained palpable vaginal mass.
  • Persistent itch, burning, pain, colour change, thickening or treatment-resistant dermatosis can precede an obvious tumour and should not be managed indefinitely without re-examination.
  • Cervical screening does not screen the vulva and is not a diagnostic rule-out test for vaginal bleeding, discharge, pain or a visible lesion.
  • Specialist examination and biopsy establish histology; cytology, swabs and visual impression alone cannot confirm or exclude invasive cancer.
  • Record lesion size, site, number, distance from the urethra, vagina and anus, and groin-node findings because these affect biopsy, imaging and treatment planning.
  • MRI pelvis defines local relationships, while CT or PET-CT may assess nodal and distant disease after histological confirmation or strong specialist suspicion.
  • Vulval squamous cancer is commonly managed with function-preserving excision and selective groin-node assessment; primary vaginal cancer is commonly managed with radiotherapy-based treatment, but every plan is stage and patient specific.
  • Continue surveillance of lichen sclerosus, differentiated vulval intraepithelial neoplasia and previous HPV-related lower-genital-tract disease because a new focal change may represent progression or recurrence.

Key red flags

An unexplained vulval lump, ulceration or bleeding meets the NICE criterion for considering a suspected-cancer pathway referral.

An unexplained palpable mass within the vagina or at its entrance meets the NICE criterion for considering a suspected-cancer pathway referral.

Persistent vulval itch, pain, burning, altered pigmentation, thickening or a lesion that fails to improve with appropriate treatment requires examination and a low threshold for specialist biopsy.

Postcoital, intermenstrual or postmenopausal bleeding, blood-stained or offensive discharge, dyspareunia, persistent vaginal itch or pain requires diagnostic assessment even when cervical screening is up to date.

A fixed lesion, urethral or anal involvement, palpable groin nodes, fistula, urinary or bowel obstruction, weight loss or severe pain suggests locally advanced or metastatic disease.

Investigation priorities

01
Consent-led vulval and pelvic examinationFirst step

Localise the symptom and identify a lesion, mass, cervical abnormality, organ involvement or palpable groin nodes.

Management branches

Primary-care recognitionExamine rather than repeatedly treating

Persistent vulval or vaginal symptoms, a new lesion, unexplained genital bleeding or treatment failure is reported.

  1. Clarify anatomy, duration, progression, bleeding, pain, discharge, prior dermatosis, HPV-related disease, immunosuppression and previous genital-tract cancer.
  2. Offer a consented external and internal examination appropriate to symptoms, documenting the lesion and groin nodes rather than relying on cervical screening or swabs.
  3. Use the suspected-cancer pathway for unexplained vulval lump, ulceration or bleeding or an unexplained palpable vaginal mass, and safety-net any other persistent unexplained symptom.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 gynaecological cancer referral recommendations
  • BGCS vulval cancer guideline update 2023
  • NHS vulval cancer symptoms
  • NHS vulval cancer tests and next steps
  • NHS vaginal cancer symptoms
  • NHS vaginal cancer tests and next steps

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom